Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

The Phillippines (1)

United Arab Emirates (1)

STADA: Executive Board gives a positive summary of financial year 2014 at the Annual General Meeting and confirms outlook for 2015

  • 03/06/2015
  • Press Release

Bad Vilbel, June 3, 2015 – 

At the Annual General Meeting of STADA Arzneimittel AG, which took place today, on June 3, 2015, Chairman of the Executive Board Hartmut Retzlaff gave a positive summary of financial year 2014 and confirmed the outlook for 2015. "In the past financial year we were once again faced with significant challenges. However, we were able to record several successes and to further strengthen our position in a global market which remains highly competitive", said Retzlaff.

In his remarks, the Chairman of the Executive Board initially discussed the major developments of financial year 2014, elaborating, among other things, on the successes achieved in the context of the active acquisition policy as well as the successful internationalization strategy. In addition, he talked about the successes that the Group achieved in the area of product development including its biosimilar activities. Toward the end of his speech, Retzlaff summarized both the growth-promoting and challenging framework conditions for the Group and confirmed the outlook for financial year 2015. With a view to the strategic success factors he showed overall optimism for continued successful development despite a difficult financial year 2015. "These success factors, coupled with a highly-motivated and very capable management team, let us to remain positive in our outlook for the STADA Group", said Retzlaff in his closing remarks.

The Annual General Meeting endorsed all of the management’s proposals. Accordingly, a dividend unchanged from the previous year of Euro 0.66 per STADA common share was resolved, with the remaining surplus being carried forward. In addition, the Executive Board and the Supervisory Board were confirmed with a high level of approval.
Today’s speech script of the Chairman of the Executive Board and the exact voting results for all items on the agenda can be found at STADA’s website at

Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / e-mail:

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / e-mail:

You will find photos of the Annual General Meeting 2015 in our press center.
> Press photos
> STADA CEO Hartmut Retzlaff - Jpg Download